A Clinical Study of TQA3605 Tablets Monotherapy or in Combination With Nucleoside (Acid) Analogues in Treatment Naive and Treated Patients With Chronic Hepatitis B

Chronic Hepatitis b Clinical Trial

Official title:

Randomized, Double-blind, Placebo-controlled Phase Ib/IIa Clinical Trial to Evaluate the Efficacy and Safety of TQA3605 Tablets Monotherapy or in Combination With Nucleoside (Acid) Analogues in Treatment-naïve Patients and Treated Patients With Chronic Hepatitis B

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06150014
• Other study ID #: TQA3605-Ib/IIa-01
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: December 7, 2023
• Est. completion date: December 2024

Study information

• Verified date: November 2023
• Source: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
• Contact: Qing Mao, Doctorc
• Phone: 13594180020
• Email: qingmao[@]yahoo.com.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a randomized, double-blind Phase Ib/IIa multicenter trial. All eligible subjects will receive TQA3605 tablets or placebo in combination with nucleoside (acid) analogues. A total of 64 subjects will be enrolled.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 64
• Est. completion date: December 2024
• Est. primary completion date: December 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Subjects voluntarily participate in this study and sign informed consent;
• Male and female, =18 years old and =70 years old (subject to the date of signing the informed consent);
• Patients diagnosed with chronic hepatitis B (CHB) who have been serum HBsAg positive for more than 6 months and HBeAg positive or negative ;
• The liver fibrosis ultrasound transient imaging elastic technology (Fibroscan/FibroTouch) showed that the liver hardness (LSM) was less than 12.4 Kpa;
• Patients with chronic hepatitis B after treatment;
• Treatment-naïve patients of chronic hepatitis B patients;

Exclusion Criteria:

• Complicated with other infected disease such as hepatitis A virus (HAV), hepatitis C virus (HCV), Hepatitis D virus (HDV), hepatitis E virus (HEV), human immunodeficiency virus (HIV), syphilis (syphilis antibody positive and need treatment determined by the investigator);
• Abdominal ultrasound or other imaging or histology showed suspected cirrhosis or other liver disease before or during screening;
• Patients have a history of hepatocellular carcinoma (HCC) before or at the time of screening, or may be at risk for HCC;
• Active autoimmune disease diagnosed with immunodeficiency or undergoing systemic therapy which was continuing within 2 weeks before first dosing;
• Currently being treated with nephrotoxic drugs or drugs that alter renal excretion;
• Abnormal thyroid function;
• Renal diseases such as chronic kidney disease and renal insufficiency or creatinine clearance (CLCr) <60 ml/min during the screening period;
• Hematologic and biochemical abnormalities;
• History of allergy to the investigational drug or its excipients;
• Recipients of solid organs or bone marrow transplants;
• A history of malignant tumors within the past 5 years;
• Interstitial lung disease, acute lung disease, etc.;
• Uncontrolled systemic diseases such as high blood pressure and diabetes;
• Have used any investigational drug or participated in a clinical trial within one month prior to the administration of study drug;
• Those who received live attenuated vaccine within 28 days before the start of study treatment, inactivated vaccine within 7 days, or planned vaccination during the study period;
• The investigator determines that there is any medical or psychiatric condition that puts the subject at risk, interferes with participation in the study, or interferes with the interpretation of the study results;
• Female subjects that were pregnant, lactating or had a positive pregnancy result during the screening period or during the trial; Male and female patients with reproductive potential who were unwilling to use effective contraceptive methods during the study period;
• Subjects who have any medical condition that may affect the absorption of oral drugs;
• Within 12 weeks prior to screening, treated chronic hepatitis B patients who had stopped taking nucleoside (acid) analogues for more than 14 consecutive days;
• Those considered unsuitable for enrollment by the investigators.

Related Conditions & MeSH terms

• Chronic Hepatitis b
• Hepatitis
• Hepatitis A
• Hepatitis B
• Hepatitis B, Chronic
• Hepatitis, Chronic

Intervention

Drug:
• Placebo
TQA3605 placebo tablets were orally administered under fast condition (at least 2 hours before or after meals) with warm water for a total of 24 weeks.
• TQA3605 tablets
TQA3605 inhibits viral replication.
• Entecavir dispersible tablets
Entecavir inhibits viral replication and indicated for chronic hepatitis B treatment.
• Tenofovir disoproxil fumarate tablet
Tenofovir disoproxil fumarate is a Nucleotide reverse transcriptase inhibitor.
• Tenofovir alafenamide fumarate tablet
Tenofovir alafenamide fumarate inhibits hepatitis B virus replication.

Locations

Country	Name	City	State
China	The First Affiliated Hospital of the Chinese People's Liberation Army Army Medical University	Chongqing	Chongqing
China	The Second Affiliated Hospital of Chongqing Medical University	Chongqing	Chongqing
China	The First Affiliated Hospital of Xi'an Jiaotong University	Xi'an	Shannxi

Sponsors (1)

Lead Sponsor	Collaborator
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The incidence of adverse events (AEs)	The incidence of adverse events (AEs) during treatment	Up to 28 weeks
Primary	Severity of adverse events (AEs)	The severity of adverse events (AEs) during treatment	Up to 28 weeks
Primary	Incidence of serious adverse events (SAEs)	The incidence of serious adverse events (SAEs) during treatment	Up to 28 weeks
Primary	Severity of serious adverse events (SAEs)	The severity of serious adverse events (SAEs) during treatment	Up to 28 weeks
Secondary	Incidence of abnormal laboratory test values	The incidence of abnormal laboratory values during treatment, e.g. triglycerides.	Up to 28 weeks
Secondary	Severity of abnormal laboratory test values	The severity of abnormal laboratory values during treatment, e.g. triglycerides.	Up to 28 weeks
Secondary	Deoxyribonucleic acid level of hepatitis B virus	Changes in hepatitis B virus deoxyribonucleic acid (HBV DNA) levels from baseline	At week 12 and week 24 or when subjects withdrawal from the study
Secondary	Hepatitis B surface antigen	Changes in serum hepatitis B surface antigen (HBsAg) from baseline	At week 12 and week 24 or when subjects withdrawal from the study
Secondary	Hepatitis B e antigen	Changes in serum hepatitis B e antigen (HBeAg) from baseline	At week 12 and week 24 or when subjects withdrawal from the study
Secondary	Serologic clearance and/or serologic conversion of HBsAg	Proportion of subjects with HBsAg serologic clearance and/or serologic conversion	At week 12 and week 24 or when subjects withdrawal from the study
Secondary	Serologic clearance and/or serologic conversion of HBeAg	Proportion of subjects with HBeAg serologic clearance and/or serologic conversion	At week 12 and week 24 or when subjects withdrawal from the study
Secondary	Virological breakthrough rate	The proportion of subjects who achieved a virological breakthrough (defined as a confirmed increase of HBV DNA levels >1.0 log10 IU/ml from the minimum during treatment).	At week 12 and week 24 or when subjects withdrawal from the study
Secondary	Peak time (Tmax)	Time to reach peak blood concentration after a single dose	pre-dose, 30 minutes, 1 , 2 , 4 , 6 , 12, 24 hours after administration on Day 1; pre-dose on Day 8 and Day 9; pre-dose, 30 minutes, 1, 2, 4, 6, 12, 24 hours after administration on Day 10.
Secondary	Peak concentration	The highest plasma drug concentration that can be achieved after medication	pre-dose, 30 minutes, 1 , 2 , 4 , 6 , 12, 24 hours after administration on Day 1; pre-dose on Day 8 and Day 9; pre-dose, 30 minutes, 1, 2, 4, 6, 12, 24 hours after administration on Day 10.
Secondary	Area under blood concentration-time curve (AUC)	The amount of drug absorbed into the human circulation after a single dose can be estimated using the area under the blood concentration-time curve	pre-dose, 30 minutes, 1 , 2 , 4 , 6 , 12, 24 hours after administration on Day 1; pre-dose on Day 8 and Day 9; pre-dose, 30 minutes, 1, 2, 4, 6, 12, 24 hours after administration on Day 10.
Secondary	Apparent volume of distribution (Vd/F)	When a drug reaches homeostasis in the body, the ratio of the amount of drug in the body to the blood concentration is called the apparent volume of distribution.	pre-dose, 30 minutes, 1 , 2 , 4 , 6 , 12, 24 hours after administration on Day 1; pre-dose on Day 8 and Day 9; pre-dose, 30 minutes, 1, 2, 4, 6, 12, 24 hours after administration on Day 10.
Secondary	Plasma clearance	The amount of plasma that the kidneys completely clear in unit time (per minute).	pre-dose, 30 minutes, 1 , 2 , 4 , 6 , 12, 24 hours after administration on Day 1; pre-dose on Day 8 and Day 9; pre-dose, 30 minutes, 1, 2, 4, 6, 12, 24 hours after administration on Day 10.
Secondary	Elimination half-life	The time it takes for the plasma concentration to drop by half.	pre-dose, 30 minutes, 1 , 2 , 4 , 6 , 12, 24 hours after administration on Day 1; pre-dose on Day 8 and Day 9; pre-dose, 30 minutes, 1, 2, 4, 6, 12, 24 hours after administration on Day 10.
Secondary	Steady state peak time	The time required to reach peak steady-state concentration after administration	pre-dose, 30 minutes, 1 , 2 , 4 , 6 , 12, 24 hours after administration on Day 1; pre-dose on Day 8 and Day 9; pre-dose, 30 minutes, 1, 2, 4, 6, 12, 24 hours after administration on Day 10.
Secondary	Steady state maximum concentration	The highest blood concentration that occurs after stabilization	pre-dose, 30 minutes, 1 , 2 , 4 , 6 , 12, 24 hours after administration on Day 1; pre-dose on Day 8 and Day 9; pre-dose, 30 minutes, 1, 2, 4, 6, 12, 24 hours after administration on Day 10.
Secondary	Steady state minimal concentration	The lowest blood concentration that occurs after stabilization	pre-dose, 30 minutes, 1 , 2 , 4 , 6 , 12, 24 hours after administration on Day 1; pre-dose on Day 8 and Day 9; pre-dose, 30 minutes, 1, 2, 4, 6, 12, 24 hours after administration on Day 10.